A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
NCT06318169
Recruiting
The study will assess the efficacy and safety of 2 dose regimens of pegozafermin for the treatment of liver fibrosis stage 2 or 3 in adult participants with MASH (previously known as nonalcoholic steatohepatitis \[NASH\]).
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
04/03/2025
Locations: 89bio Clinical Study Site, Birmingham, Alabama +208 locations
Conditions: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis
Register for Updates
Concentration of Ofatumumab in the Breast Milk of Lactating Women With Relapsing Forms of Multiple Sclerosis
NCT06444113
Recruiting
This study will evaluate whether ofatumumab is excreted at quantifiable levels and at which concentrations in breast milk of lactating women with RMS). The study will include lactating mothers who plan to breastfeed and initiate/re-initiate ofatumumab 2-24 weeks post-partum.
Gender:
FEMALE
Ages:
Between 18 years and 100 years
Trial Updated:
04/03/2025
Locations: UCSF, San Francisco, California +11 locations
Conditions: Multiple Sclerosis
Register for Updates
Prevail Global Study
NCT06535854
Recruiting
The purpose of the study is to evaluate the clinical safety and efficacy of the Prevail DCB.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/03/2025
Locations: Cumc/Nyph, New York, New York +1 locations
Conditions: Coronary Artery Disease
Register for Updates
A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients With Advanced Solid Tumors
NCT06619587
Recruiting
This is a first-in-human Phase I/II, open-label, multicenter, dose-escalation and expansion study designed to evaluate the safety, pharmacokinetics, and preliminary activity of GDC-7035 as a single agent and in combination with other anti-cancer therapies in participants with advanced or metastatic solid tumors that harbor the KRAS G12D mutation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/03/2025
Locations: Yale Cancer Center, New Haven, Connecticut +2 locations
Conditions: Solid Tumor
Register for Updates
Study of d-MAPPS™ Ophthalmic Solution, Safety, Tolerability, and Efficacy in the Treatment of Chronic Ocular Graft-Versus-Host Disease (oGVHD)
NCT06852768
Recruiting
A Double-Masked, Randomized, Placebo-Controlled Study of the Safety and Tolerability and Efficacy of d-Mapps™ Opthalmic Solution in the Treatment of Chronic Oscular Graft-Versus-Host Disease (oGHVD)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/03/2025
Locations: Beach Eye Medical Group, Huntington Beach, California +3 locations
Conditions: OGHVD
Register for Updates
YAG Laser Vitreolysis for Vitreous Floaters
NCT06915922
Recruiting
The purpose of this study is to measure how the quality of life, the structure of eye, and vision change after treatment for the opacities in the gel (vitreous) that fills the center of eye which cause vision disturbances commonly called "floaters". In this study the vitreous floaters are treated using a Neodymium-doped yttrium-aluminum-garnet (Nd:YAG) laser. The FDA has approved the use of this laser to treat membranes in the eye.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/03/2025
Locations: VMR Institute for Vitreous Macula Retina, Huntington Beach, California
Conditions: Posterior Vitreous Detachment, Myopic Vitreopathy, VISION DEGRADING MYODESOPSIA
Register for Updates
HDClarity: a Multi-site Cerebrospinal Fluid Collection Initiative to Facilitate Therapeutic Development for Huntington's Disease
NCT02855476
Recruiting
HDClarity will seek at least 2500 research participants at different stages of Huntington's disease (HD). The primary objective is to collect a high quality CSF sample for evaluation of biomarkers and pathways that will enable the development of novel treatments for HD. The secondary objective is to generate a high quality plasma sample collection matching the CSF collections, which will also be used to evaluate biomarkers and pathways of relevance to HD research and development.
Gender:
ALL
Ages:
Between 11 years and 75 years
Trial Updated:
04/03/2025
Locations: Cenexel, Englewood, Colorado +38 locations
Conditions: Huntington's Disease
Register for Updates
WSD0922-FU for the Treatment of Glioblastoma, Anaplastic Astrocytoma, or Non-small Cell Lung Cancer With Central Nervous System Metastases
NCT04197934
Recruiting
This phase I trial studies the side effects and best dose of WSD0922-FU for the treatment of glioblastoma, anaplastic astrocytoma, or non-small cell lung cancer that has spread to the central nervous system (central nervous system metastases). WSD0922-FU is a targeted treatment which blocks the EGFR protein - a strategy that has led to a lot of benefit in patients with many different cancers. WSD0922-FU may also be able to get into cancers in the brain and spinal cord and help patients with brai... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/03/2025
Locations: Mayo Clinic in Arizona, Scottsdale, Arizona +2 locations
Conditions: Anaplastic Astrocytoma, IDH-Wildtype, Glioblastoma, IDH-Wildtype, Metastatic Malignant Neoplasm in the Central Nervous System, Metastatic Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Register for Updates
WE-TRUST (Workflow Optimization to Reduce Time to Endovascular Reperfusion for Ultra-fast Stroke Treatment)
NCT04701684
Recruiting
The WE-TRUST study is a multi-center randomized clinical trial to assess the impact of a Direct to Angio Suite (DTAS) workflow on stroke patient outcomes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/03/2025
Locations: Baptist Medical Center, Jacksonville, Florida +19 locations
Conditions: Stroke, Acute
Register for Updates
Long-term Observation of Participants With Mood Disorders
NCT04877977
Recruiting
Background: More than 12,000 people have taken part in research at the Experimental Therapeutics \& Pathophysiology Branch at the National Institute of Mental Health Intramural Program. This has led to advances in the treatment of depression, bipolar disorder, and suicide risk. Researchers want to follow up with this group to see if they continue to have mental health symptoms and receive psychiatric treatments. Objective: To learn the long-term impact of depression, bipolar disorder, and sui... Read More
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
04/03/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Depression, Suicide Risk
Register for Updates
Neostigmine and Glycopyrrolate for the Treatment of Headache After Dural Puncture
NCT05116930
Recruiting
The purpose of this study is to evaluate Neostigmine and Glycopyrrolate to treat post-dural puncture headache (PDPH) to reduce the proportion of postpartum women with a PDPH requiring epidural blood patch (EBP) who developed a PDPH after accidental dural puncture.
Gender:
FEMALE
Ages:
Between 18 years and 54 years
Trial Updated:
04/03/2025
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Post-Dural Puncture Headache
Register for Updates
COVID-19 Coagulopathy Extension Study
NCT05334615
Recruiting
At the University of Iowa, the investigators led a multicenter randomized clinical trial comparing standard prophylactic dose to intermediate dose enoxaparin in hospitalized patients with COVID-19 (NCT04360824). As part of an exploratory biomarker component of this trial, blood samples were collected from hospitalized COVID-19 patients at enrollment and weekly for up to 30 days of hospitalization. The pilot results, as well as reports from other groups, demonstrate increased potential for thromb... Read More
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
04/03/2025
Locations: University of Iowa Health Care, Iowa City, Iowa
Conditions: COVID-19
Register for Updates